NovaBridge Biosciences Files for Dual Listing on Hong Kong Stock Exchange

NovaBridge Biosciences has filed a Listing Application with the Hong Kong Stock Exchange for a proposed dual primary listing of its ordinary shares, along with an initial public offering. The application includes new and supplemental descriptions of the company's business and financial information as required by the Hong Kong Stock Exchange Listing Rules. This filing also updates certain disclosures previously made in the company's 2024 Form 20-F. The company emphasizes that there is no assurance as to if or when the Listing and Offering will take place. The filing also includes forward-looking statements regarding the company's future operations, clinical trials, and regulatory approvals, which are subject to various risks and uncertainties. The company has also adopted a new business model to identify and advance high-value therapeutic assets through strategic partnerships and specialized subsidiary entities.